Galvanize Therapeutics closed an oversubscribed USD 130 million Series D led by HealthQuest Capital. Olympus Innovation Ventures and Braidwell joined as new investors, alongside existing backers. The Redwood City company develops pulsed electric field technologies for oncology and chronic lung disease. It says the financing will support commercial expansion of its Aliya platform, clinical evidence work, advancement of RheOx therapy and development of next-generation products. Regulatory, procedure and performance claims remain company reported. The amount, stage, lead and announced use of funds were confirmed through the company release and separate adviser coverage.
Galvanize Therapeutics raises USD 130m Series D
HealthQuest Capital leads financing for pulsed electric field devices.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


